Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
 - EconoTimes)
RANCHO CORDOVA, Calif., Feb. 28, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Phil Coelho, chief technology officer of ThermoGenesis Corp., Cesca’s device division, will be presenting at the 8th Spring Meeting of the International Society for BioProcess Technology (ISBiotech). ISBiotech is being held March 5-7, 2018 at the Hilton Norfolk The Main Hotel in Norfolk, Virginia.
Mr. Coelho’s presentation, “Automated, Closed System Manufacturing of CAR-T Cells,” is scheduled to take place on Wednesday, March 7 from 1:30-2:15pm EST.
For more information about the ISBiotech Spring Meeting, go to: www.isbiotech.org
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
